| Outcome Measures: |
Primary: Mean sitting systolic blood pressure (MSSBP) (ATB-1011+ATB-1012 vs. ATB-1012), Change in MSSBP with ATB-1011 + ATB-1012 co-administration compared to ATB-1012 monotherapy, baseline to Week 12|Hemoglobin A1c (HbA1c) (ATB-1011+ATB-1012 vs. ATB-1011), Changes in HbA1c with ATB-1011 + ATB-1012 co-administration compared to ATB-1011 monotherapy, baseline to Week 12 | Secondary: MSSBP (ATB-1011+ATB-1012 vs. ATB-1011), Changes in MSSBP with ATB-1011 + ATB-1012 co-administration compared to ATB-1011 monotherapy, baseline to Week 12|MSSBP (ATB-1012+ATB-1013 vs. ATB-1012), Changes in MSSBP with ATB-1012 + ATB-1013 co-administration compared to ATB-1012 monotherapy, baseline to Week 12|MSSBP (ATB-1012+ATB-1013 vs ATB-1011+ATB-1012), Changes in MSSBP with ATB-1012 + ATB-1013 co-administration compared to ATB-1011 + ATB-1012 co-administration, baseline to Week 12|HbA1c (ATB-1011+ATB-1012 vs. ATB-1012), Changes in HbA1c with ATB-1011 + ATB-1012 co-administration compared to ATB-1012 monotherapy, baseline to Week 12|Changes in MSSBP, baseline to Weeks 4 and 8|Changes in mean sitting diastolic blood pressure (MSDBP), baseline to Weeks 4, 8, and 12|Changes in HbA1c, baseline to Weeks 4, 8, and 12|Changes in glycemic parameters, Fasting plasma glucose (FPG), baseline to Weeks 4, 8, and 12|Changes in glycemic parameters, Homeostatic model assessment of beta cell function (HOMA-beta), baseline to Weeks 4, 8, and 12|Changes in glycemic parameters, Homeostatic model assessment of insulin resistance (HOMA-IR), baseline to Weeks 4, 8, and 12 | Other: Extension period: Changes in HbA1c, baseline and Week 12 to Weeks 18 and 24|Extension period: Changes in MSSBP, baseline and Week 12 to Weeks 18 and 24|Extension period: Changes in MSDBP, baseline and Week 12 to Weeks 18 and 24
|
